从行业趋势来看，中国护肤品牌在下半场的竞争逻辑已经清晰： 真正的增长，将由科研驱动；真正的品牌力，将由科研力决定。 当竞争进入下半场，品牌要赢得的是"科研方向""科研深度"与"科研转化能力"。方向意味着能否做出有 战略高度的决策；深度取决于是否拥有自主知识产权与基础研究积累；转化能力则反映在能否把科研成 果快速落地、开发成有实证、有体验、有复购的产品。科研需要闭环，要有方向、有验证、有应用，才 能发挥出科研最大的价值。 海尼全球研发中心的出现，正是围绕这三点的系统化回答： 第一，在科研战略方向上，明确全球+本土的双枢纽科研体系，建立长期可持续的创新引擎。 第二，在科研深度上，海尼荣誉首席科学家康斯坦丁·诺沃肖洛夫（2010年诺贝尔物理学奖得主）与近 40人的博士级科研团队，共同攻坚成分创新等前沿科研课题；并通过海外联合实验室、海尼功效护肤科 研联盟，持续产出科研成果。 第三，在科研转化能力上，海尼将依托集团各大品牌可逐KAZOO、笔薇BUV、白云山等落地最新功效 护肤科研成果，带来实效、实证的"下一代"护肤产品。 12月1日，海尼全球研发中心在广州正式启幕，来自科研机构、知名高校、重点供应链企业以及政府相 关 ...

Core Insights - The inauguration of the Haini Global R&D Center in Guangzhou marks a significant milestone in skincare research, enhancing China's capabilities in this sector [1][2] - Haini Group, established in 2012, focuses on efficacy skincare and has rapidly grown its consumer base, positioning itself as a new force in domestic skincare [1] - The R&D center spans nearly 7,000 square meters and can accommodate over 300 researchers, with a current team of nearly 40 multidisciplinary experts, including 33% PhD holders [1][2] Company Developments - Haini Group has launched the "Haini Efficacy Skincare Research Alliance" in collaboration with Nobel laureate Konstantin Novoselov and professors from top universities, aiming to integrate and share industry research outcomes [2] - The company has committed an initial "billion-level research special fund," demonstrating its long-term investment strategy in research [2] - The establishment of the R&D center is expected to enhance Guangzhou's position as a hub for skincare research, contributing to the local beauty industry ecosystem [2] Industry Context - As of 2024, Guangzhou is home to over 5,500 cosmetics-related enterprises, accounting for more than one-third of the national total, making it a key player in the beauty industry [2] - Despite the large number of companies, high-level institutions with original research and clinical validation systems remain scarce, highlighting the importance of the new R&D center [2] - The center aims to create a dual hub research system that combines local insights with global perspectives, enhancing the competitiveness of domestic skincare brands on an international scale [2]

Core Viewpoint - The launch of the Xihe Guanggu Optoelectronic Industry Incubator signifies the establishment of a collaborative model involving government, research, and capital, aimed at fostering innovation in the optoelectronic sector [1] Group 1 - The Xihe Guanggu Optoelectronic Industry Incubator was inaugurated on November 22, marking a significant development in the optoelectronic industry [1] - The incubator is a joint initiative by Shanghai Guotou Company, the Jiading District People's Government, and the Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences [1] - The collaboration emphasizes a model of "government platform, research-driven, and capital empowerment" [1] Group 2 - Shanghai Guotou Company, along with Jiading KET Investment Group and Hangzhou Zhongke Shenguang Equity Investment Co., Ltd., has initiated the "Shanghai Huiguang Xihe Venture Capital Fund" project [1] - This venture capital fund aims to support startups in the optoelectronic industry, enhancing investment opportunities in the sector [1]

Core Viewpoint - The company is positioning itself as a "research-driven" brand by focusing on scientific evidence for its product claims and emphasizing foundational research over mere marketing [1][4]. Group 1: Product Development and Innovation - The company emphasizes the importance of understanding not just the ingredients used in products, but also the rationale behind their effectiveness, showcasing its foundational research capabilities [1]. - A breakthrough ingredient, "human-like exosome HME," was introduced at a research conference, highlighting the company's proprietary technology in developing advanced anti-aging solutions [1][3]. Group 2: Safety, Efficacy, and Compliance - The new ingredient is designed with safety in mind, utilizing patented high-precision engineering technology to eliminate risk factors associated with human-derived exosomes [3]. - The efficacy of the ingredient is enhanced through artificial synthesis that mimics human exosome structures, incorporating targeted peptides and gene-level components, resulting in superior anti-aging effects compared to traditional human exosomes [3]. - All components of the new ingredient are compliant with the "Catalog of Used Cosmetic Ingredients" and have received national patent authorization, ensuring regulatory adherence and intellectual property protection [3]. Group 3: Long-term Investment in Research - The company plans to invest 2 billion yuan in research and development over the next decade, supported by established research centers and certified laboratories, ensuring a robust foundation for product reliability [3]. - The company’s integrated model covering "research-production-raw materials" allows for stringent quality control from the raw material stage, enhancing product stability and consistency [3]. Group 4: Evolution of Research Capabilities - The introduction of "human-like exosome HME" signifies the company's advancement into modern biological research, moving beyond plant-based ingredients to cellular and genetic regulation [4].

Core Insights - Shenzhen Haichuang Biotechnology Co., Ltd., the parent company of the immune anti-aging brand Haipuno, completed a multi-million RMB Series A financing round on October 17, 2023, led by Sanze Venture Capital, with Guangyuan Capital serving as the exclusive financial advisor [1][2] - The funds from this financing round will primarily be used for new product development, brand building, and team expansion [1] - Haichuang Biotechnology has a strong background in technological innovation, having been recognized as a "seed unicorn enterprise" at the China (Shenzhen) Unicorn Enterprise Conference in July 2025 [1] Financing History - The company has undergone multiple financing rounds, including: - Series A on October 17, 2023, amounting to several tens of millions RMB [2] - Pre-A+ round on February 21, 2023, also amounting to several tens of millions RMB [2] - Pre-A round on April 10, 2022, with nearly ten million RMB raised [2] - The increasing capital interest reflects a preference for "research-driven, efficacy-oriented" brands in the competitive cosmetics industry [2] Company Background - Founded in 2020 by Professor Liu Zhigang and Dr. Wang Zhiyao, Haichuang Biotechnology leverages over 30 years of immunology research from Shenzhen University [4] - The company focuses on developing functional skincare products, probiotics, and bioactive raw materials, aiming for a comprehensive layout across "cosmetics, food, medicine, and devices" [4] - The R&D team has published over 300 academic papers related to immunology, with more than 60% holding doctoral degrees [4] Product Performance - The Haipuno skincare series achieved total sales of 50 million RMB from 2023 to March 2024, with a stable repurchase rate of over 60% [5] - The company’s proprietary ingredient HEPRO-6A® has won multiple innovation awards and is central to its product offerings [4][7] Market Strategy - The recent financing indicates strong market recognition and effective sales conversion driven by robust scientific research [6] - The company is set to upgrade its proprietary ingredient to HEPRO-6A PRO in 2024, enhancing its efficacy [7] - Haichuang Biotechnology is also developing functional probiotic products and medical devices for specific skin conditions, indicating a broadening of its product portfolio [9] Industry Trends - The financing reflects a broader trend in the cosmetics industry towards technology-driven and comprehensive product offerings, as consumer demand for efficacy increases [7] - The company's strategy of integrating research, product development, and market engagement serves as a model for other technology-oriented enterprises in the sector [7]

Core Viewpoint - The article highlights significant personnel changes in the beauty industry, indicating a shift towards a research-driven, globalized, and organizationally transformed competitive landscape, with three main focal points: the emergence of new roles, expanded responsibilities for foreign beauty giants in the Chinese market, and widespread organizational restructuring [2][3][26]. Group 1: Emergence of New Roles - Over 75 key positions have changed among 25 leading beauty companies in the first half of 2025, with a notable rise in roles focused on digitalization, research, innovation, and marketing communication, reflecting the industry's future direction [2][6]. - Estee Lauder has created three new positions, including Chief Digital and Marketing Officer, Global Scientific Sleep Advisor, and President of the Makeup Brand Group, indicating a strategic shift towards integrating scientific expertise into product development [8][10]. - L'Oreal has appointed a Chief Innovation and Strategic Outlook Officer to oversee innovation teams and strategic foresight, emphasizing the importance of future-oriented innovation in the beauty sector [12]. Group 2: Expanded Responsibilities in the Chinese Market - International beauty companies are elevating their China market leaders to global decision-making roles, marking a significant shift in strategic positioning [14][24]. - Estee Lauder's new CEO has made substantial adjustments, including promoting the China President to the global management team, breaking previous decision-making chains [15][16]. - Shiseido has appointed a dual-role CEO for China and travel retail, merging management of these two growth engines to maximize synergies [17][19]. Group 3: Organizational Restructuring - The beauty industry is undergoing a deep transformation, moving from high growth to high-quality growth, as evidenced by widespread organizational changes [3][26]. - Companies are restructuring their organizational frameworks to enhance the integration of research and market strategies, with a focus on consumer needs [36][37]. - Estee Lauder's new strategy involves a significant operational transformation, restructuring brands by categories for better management and growth [31][34].